Literature DB >> 10588928

(-)1-(Benzofuran-2-yl)-2-propylaminopentane, [(-)BPAP], a selective enhancer of the impulse propagation mediated release of catecholamines and serotonin in the brain.

J Knoll1, F Yoneda, B Knoll, H Ohde, I Miklya.   

Abstract

1. The brain constituents beta-phenylethylamine (PEA) and tryptamine enhance the impulse propagation mediated transmitter release (exocytosis) from the catecholaminergic and serotoninergic neurons in the brain ('catecholaminergic/serotoninergic activity enhancer, CAE/SAE, effect'). (-)Deprenyl (Selegiline) and (-)1-phenyl-2-propylaminopentane [(-)PPAP] are amphetamine derived CAE substances devoid of the catecholamine releasing property. 2. By changing the aromatic ring in PPAP we developed highly potent and selective CAE/SAE substances, structurally unrelated to the amphetamines. Out of 65 newly synthetized compounds, a tryptamine derived structure, (-)1-(benzofuran-2-yl)-2-propylaminopentane [(-)BPAP] was selected as a potential follower of (-)deprenyl in the clinic and as a reference compound for further analysis of the CAE/SAE mechanism in the mammalian brain. 3. (-)BPAP significantly enhanced in 0.18 micromol 1(-1) concentration the impulse propagation mediated release of [(3)H]-noradrenaline and [(3)H]-dopamine and in 36 nmol 1(-1) concentration the release of [(3)H]-serotonin from the isolated brain stem of rats. The amount of catecholamines and serotonin released from isolated discrete rat brain regions (dopamine from the striatum, substantia nigra and tuberculum olfactorium, noradrenaline from the locus coeruleus and serotonin from the raphe) enhanced significantly in the presence of 10(-12) - 10(-14) M (-)BPAP. BPAP protected cultured hippocampal neurons from the neurotoxic effect of beta-amyloid in 10(-14) M concentration. In rats (-)BPAP significantly enhanced the activity of the catecholaminergic and serotoninergic neurons in the brain 30 min after acute injection of 0.1 microg kg(-1) s.c. In the shuttle box, (-)BPAP in rats was about 130 times more potent than (-)deprenyl in antagonizing tetrabenazine induced inhibition of performance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10588928      PMCID: PMC1571822          DOI: 10.1038/sj.bjp.0702995

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  29 in total

1.  Treatment with L-deprenyl prolongs life in elderly dogs.

Authors:  W W Ruehl; T L Entriken; B A Muggenburg; D S Bruyette; W C Griffith; F F Hahn
Journal:  Life Sci       Date:  1997       Impact factor: 5.037

2.  Effect of deprenyl on the progression of disability in early Parkinson's disease.

Authors: 
Journal:  N Engl J Med       Date:  1989-11-16       Impact factor: 91.245

3.  Maintenance on L-deprenyl prolongs life in aged male rats.

Authors:  N W Milgram; R J Racine; P Nellis; A Mendonca; G O Ivy
Journal:  Life Sci       Date:  1990       Impact factor: 5.037

4.  Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

Authors:  J Knoll; Z Ecseri; K Kelemen; J Nievel; B Knoll
Journal:  Arch Int Pharmacodyn Ther       Date:  1965-05

5.  Some puzzling pharmacological effects of monoamine oxidase inhibitors.

Authors:  J Knoll; K Magyar
Journal:  Adv Biochem Psychopharmacol       Date:  1972

6.  L-deprenyl, a selective monoamine oxidase type-B inhibitor in endogenous depression.

Authors:  J Mann; S Gershon
Journal:  Life Sci       Date:  1980-03-17       Impact factor: 5.037

7.  Determination of monoamine oxidase.

Authors:  K F Tipton
Journal:  Methods Find Exp Clin Pharmacol       Date:  1985-07

8.  Striatal dopamine, sexual activity and lifespan. Longevity of rats treated with (-)deprenyl.

Authors:  J Knoll; J Dallo; T T Yen
Journal:  Life Sci       Date:  1989       Impact factor: 5.037

9.  The effect of deprenyl (selegiline) on the natural history of Parkinson's disease.

Authors:  J W Tetrud; J W Langston
Journal:  Science       Date:  1989-08-04       Impact factor: 47.728

10.  The striatal dopamine dependency of life span in male rats. Longevity study with (-)deprenyl.

Authors:  J Knoll
Journal:  Mech Ageing Dev       Date:  1988-12       Impact factor: 5.432

View more
  6 in total

1.  (-)1-(Benzofuran-2-yl)-2-propylaminopentane shows survival effect on cortical neurons under serum-free condition through sigma receptors.

Authors:  W Hamabe; R Fujita; T Yasusa; F Yoneda; A Yoshida; H Ueda
Journal:  Cell Mol Neurobiol       Date:  2000-12       Impact factor: 5.046

Review 2.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

Review 3.  Enhancer regulation/endogenous and synthetic enhancer compounds: a neurochemical concept of the innate and acquired drives.

Authors:  Joseph Knoll
Journal:  Neurochem Res       Date:  2003-08       Impact factor: 3.996

4.  Inhibitory Effect of (2R)-1-(1-Benzofuran-2-yl)-N-propylpentan-2-amine on Lung Adenocarcinoma.

Authors:  Zsolt Mervai; Andrea Reszegi; Ildikó Miklya; József Knoll; Zsuzsa Schaff; Ilona Kovalszky; Kornélia Baghy
Journal:  Pathol Oncol Res       Date:  2019-02-08       Impact factor: 3.201

5.  Enhancer Regulation of Dopaminergic Neurochemical Transmission in the Striatum.

Authors:  Laszlo G Harsing; Joseph Knoll; Ildiko Miklya
Journal:  Int J Mol Sci       Date:  2022-08-01       Impact factor: 6.208

6.  The fate of (-)1-(benzofuran-2-yl)-2-propylaminopentane . HCl, (-)-BPAP, in rats, a potent enhancer of the impulse-evoked release of catecholamines and serotonin in the brain.

Authors:  Kálmán Magyar; Joseph Lengyel; Andrea Bolehovszky; Bertha Knoll; Iidikó Miklya; Joseph Knoll
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Jul-Sep       Impact factor: 2.569

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.